Intracellular Activation of Interferon Regulatory Factor-1 by Nanobodies to the Multifunctional (Mf1) Domain by Moeller, Angeli et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intracellular Activation of Interferon Regulatory Factor-1 by
Nanobodies to the Multifunctional (Mf1) Domain
Citation for published version:
Moeller, A, Pion, E, Narayan, V & Ball, KL 2010, 'Intracellular Activation of Interferon Regulatory Factor-1 by
Nanobodies to the Multifunctional (Mf1) Domain' Journal of Biological Chemistry, vol. 285, no. 49, pp.
38348-38361. DOI: 10.1074/jbc.M110.149476
Digital Object Identifier (DOI):
10.1074/jbc.M110.149476
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Biological Chemistry
Publisher Rights Statement:
Copyright © 2010 by The American Society for Biochemistry and Molecular Biology, Inc
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Narayan and Kathryn L. Ball
Angeli Möller, Emmanuelle Pion, Vikram
  
Multifunctional (Mf1) Domain
Regulatory Factor-1 by Nanobodies to the 
Intracellular Activation of Interferon
Gene Regulation:
doi: 10.1074/jbc.M110.149476 originally published online September 3, 2010
2010, 285:38348-38361.J. Biol. Chem. 
  
 10.1074/jbc.M110.149476Access the most updated version of this article at doi: 
  
.JBC Affinity SitesFind articles, minireviews, Reflections and Classics on similar topics on the 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
Supplemental material:
  
 http://www.jbc.org/content/suppl/2010/09/03/M110.149476.DC1.html
  
 http://www.jbc.org/content/285/49/38348.full.html#ref-list-1
This article cites 54 references, 23 of which can be accessed free at
 by guest on August 9, 2013http://www.jbc.org/Downloaded from 
Intracellular Activation of Interferon Regulatory Factor-1 by
Nanobodies to the Multifunctional (Mf1) Domain*□S
Received for publication, June 2, 2010, and in revised form, September 3, 2010 Published, JBC Papers in Press, September 3, 2010, DOI 10.1074/jbc.M110.149476
Angeli Mo¨ller1, Emmanuelle Pion, Vikram Narayan, and Kathryn L. Ball2
From the Cell Signalling Unit, University of Edinburgh Cancer Research UK Centre, Crewe Road South,
Edinburgh EH4 2XR, Scotland, United Kingdom
IRF-1 is a tumor suppressor protein that activates gene
expression from a range of promoters in response to stimuli
spanning viral infection to DNA damage. Studies on the post-
translational regulation of IRF-1 have been hampered by a lack
of suitable biochemical tools capable of targeting the endoge-
nous protein. In this study, phagedisplay technologywas used to
develop a monoclonal nanobody targeting the C-terminal Mf1
domain (residues 301–325) of IRF-1. Intracellular expression of
the nanobody demonstrated that the transcriptional activity of
IRF-1 is constrained by the Mf1 domain as nanobody binding
gave an increase in expression from IRF-1-responsive promot-
ers of up to 8-fold. Furthermore,Mf1-directed nanobodies have
revealed an unexpected function for this domain in limiting the
rate atwhich the IRF-1protein is degraded.Thus, the increase in
IRF-1 transcriptional activity observed on nanobody binding is
accompanied by a significant reduction in the half-life of the
protein. In support of the data obtained using nanobodies, a
single pointmutation (P325A) involving the C-terminal residue
of IRF-1 has been identified, which results in greater transcrip-
tional activity and a significant increase in the rate of degrada-
tion. The results presented here support a role for the Mf1
domain in limiting both IRF-1-dependent transcription and the
rate of IRF-1 turnover. In addition, the data highlight a route for
activation of downstream genes in the IRF-1 tumor suppressor
pathway using biologics.
The skipping of exon 3 and/or 2 seen in transcripts for the
IRF-1 tumor suppressor has been linked to the development of
human hemopoietic malignancies, such as leukemia and
myelodysplastic syndrome (1–3). More recently, the loss of
exons 7–9 in various combinations has been reported in cervi-
cal cancer, and this leads to the generation of C-terminally
truncated IRF-1 that can compete with the wild-type protein
for DNA binding. The C-terminal mutants have longer half-
lives and, unlikewild-type IRF-1, can be expressed in a cell cycle
independent manner (4). Understanding the function of the
Mf1 domain of IRF-1, a regulatory subdomain that is located at
the C terminus of the protein, could therefore increase our cur-
rent knowledge of the role that truncated proteins play in
tumor progression.
The extreme C-terminal region of IRF-1 (Mf1 domain;
amino acids 301–325) is a regulatory domain that plays a role in
both positive and negative modulation of target gene expres-
sion (5). In addition, theMf1 domain plays a role in determining
the rate of IRF-1 protein degradation, with removal of the C
terminus leading to a significant increase in the half-life of the
protein (6, 7). Furthermore, binding of members of the Hsp70
family of molecular chaperones to the Mf1 domain appears to
be critical for the normal function and regulation of IRF-1 (8).
Thus previous studies have pointed to a potentially important
role for the Mf1 domain of IRF-1 in its homeostatic regulation.
The studies described above, by necessity, relied on the use of
exogenous IRF-1 mutant proteins; therefore, we do not know
whether the Mf1 domain is rate-limiting for IRF-1-mediated
gene activation within the context of the endogenous protein.
To address this issue, we have used antibody phage display to
screen for scFv3 antibody fragments (9, 10) to the Mf1 domain.
The introduction of scFv nanobodies into a cell system showed
that the Mf1 domain was rate-limiting for IRF-1-mediated
transcription under normal cellular conditions, providing good
evidence that IRF-1 transcriptional function is subject to post-
translational regulation. The data also highlight an unexpected
role for the extreme C terminus in the negative regulation of
IRF-1 turnover.
MATERIALS ANDMETHODS
Reagents andCells—Anti-IRF-1 (BDBiosciences), anti-IRF-1
C20 (Santa Cruz Biotechnology), anti-IRF-2 (Abcam), anti-His
(Novagen), anti-HP1 (Millipore), anti-caspase3 (Santa Cruz
Biotechnology), anti-ISG20 (Abnova), anti-PKR (Santa Cruz
Biotechnology), anti-CDK2 (Santa Cruz Biotechnology), anti-
GAPDH (Abcam), and anti-GFP (Clontech) were used at a
1:1000 dilution; and HRP-protein A (BD Biosciences) was used
at 1 g/ml. Cycloheximide (Supelco) was dissolved in H2O to 5
mg/ml and used at a concentration of 30 g/ml. MG132 (Cal-
biochem) was dissolved in DMSO to 10 mM and used at 50 M.
pcDNA3-IRF-1 and IRF-1 C25 were as described previously
(5); pcDNA3 IRF-1 P325A was made using a QuikChange site-
directed mutagenesis kit. A375 and HeLa cells were cultured in
DMEM (Invitrogen) supplemented with 10% (v/v) FBS and 1%
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penicillin/streptomycin at 37 °C and 10% CO2. Cells were
transfected at 80% confluence using Attractene (Qiagen).
Generation of Anti-IRF-1 scFv Antibodies—Biotin-SGSG-
linked peptide (LDSLLTPVRLPSIQAIPCAP) was immobilized
on an immunotube (Nunc) pre-coated with 20 g/ml strepta-
vidin. The Tomlinson I and J Human Single Fold scFv Libraries
(Geneservice) were used for three rounds of selection following
themanufacturer’s protocol. scFvwere expressed fromHB2151
bacteria infected with scFv displaying phage. Expression was
induced with 9 mM isopropyl 1-thio--D-galactopyranoside,
shaking at 30 °C overnight. A nitrocellulose membrane was
incubated with 0.3 g/l GST-IRF-1 in PBS and blocked for 30
min in 5% milk in PBS, 0.1% Tween. Each monoclonal scFv (2
l) was dotted onto the membrane and incubated for 1 h at
room temperature in a humidified chamber. The membrane
was overlaid with 1:1000 protein A-HRP in PBS, 0.1% Tween
with 5% milk for 1 h. Between each step, the membrane was
washed extensively with PBS, 0.1% Tween, and antibody bind-
ing was detected using enhanced chemiluminescence. For
amplification of phage and DNA extraction, KM13 helper
phage (1 109) were added to 500 l of TG1 bacterial cultures
(2 TY, 100 g/ml ampicillin, 1% glucose) infected with phage
displaying anti-IRF-1 monoclonal antibodies and incubated
without shaking at 37 °C for 30 min. The cultures were centri-
fuged at 3000 g for 10 min, and the pellet was resuspended in
500 l of 2 TY (100 g/ml ampicillin, 50 g/ml kanamycin,
and 0.1% glucose) for overnight incubation with shaking at
30 °C. The culture was centrifuged (3300  g for 30 min), and
phage were precipitated from the supernatant by adding 200 l
of PEG/NaCl (20% polyethylene glycol 6000, 2.5 M NaCl) for
10–20 min at room temperature. Phage were pelleted
(16,100  g for 10 min at 4 °C) and resuspended in 100 l of
Iodide Buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 4 M NaI).
The suspension was incubated with ethanol (250 l) for 10–20
min at room temperature. Precipitated phage DNA was col-
lected by centrifugation (16,100 g for 10min at 4 °C), washed
with 0.5ml of 70% (v/v) ethanol, recentrifuged, and dried briefly
under vacuum. For the subsequent sequencing and PCR, the
DNA was suspended in TE buffer and quantified using a spec-
trophotometer (Nanodrop ND-1000). The anti-IRF-1 scFv
were cloned into pDEST 15, pDEST 14, and pDEST 53 for
expression in bacterial and mammalian systems using Gate-
way technology (Invitrogen). For in vitro studies, the scFv
nanobodies were purified on Ni-NTA-agarose (Qiagen) or
glutathione-Sepharose.
Immunoblots and Binding Assays—Peptide binding assays
were carried out as described previously (11); scFv binding was
detected using anti-His mAb and enhanced chemilumines-
cence. The protein binding assays were as described previously
(8). For immunoblots, mammalian cells were lysed in 5
reporter lysis buffer (Promega) or 0.1% Triton lysis buffer and
processed as described previously (8).
EMSA and Reporter Assays—EMSAs were carried out with a
C1 probe using a protocol based on that of Fujita et al. (20).
Briefly, 2 l of 6 IRF-1 EMSA buffer (120 mMHEPES, pH 7.5,
300 mM KCl, 30% glycerol, 2.4 mM DTT, 0.6 mg/ml BSA, 3%
Triton X-100), 1.5 l of nonspecific DNA (1 l of 1 g/l
poly(dI-dC) and 0.5 l of 1 g/l salmon sperm DNA), and
GST-IRF-1 plus or minus various antibodies (as detailed in the
figure legends) were preincubated for 30min on ice prior to the
addition of 32P-labeled C1 probe (1 l). Following a further
30-min incubation at room temperature, the reactions were
analyzed on a 5% polyacrylamide gel, and radiolabeled bands
were detected using a phosphoimager. Luciferase reporter
assays were carried out as described previously (5, 12) using 120
ng of either p125-luc IFN (which contains the human IFN-
promoter region 125 to 19) or a control plasmid p55-luc
IFN (minus the ISRE; promoter region 55 to 19), which
were the kind gifts fromDr. T. Fujita (KyotoUniversity), TLR3-
Luc (hTLR3–588 or hTLR3IRF a mutant which is minus the
ISRE) (19), -683Cdk2-Luc (5), TRAIL (pTRL3 or a mutant
minus the ISRE/IRFE, pTRL3n6) (13), and IL-7 (609-Luc or a
mutant, 609-mtIRF-E-Luc which is missing the ISRE) (14).
Reporter activity was determined 24 h post-transfection.
scFv Protein Pulldowns—Purified scFv (1 g) in buffer A (20
mM Tris-HCl, pH 7.5, 0.5 M NaCl) was incubated with Ni2-
NTA-agarose (15 l) for 1 h at 4 °C and then washed two times
for 5 min with buffer A plus 5 mM imidazole. The beads were
subsequently incubated with HeLa cell lysate (500 g) and
mixed at 4 °C for 2 h.Unboundproteinswere removed bywash-
ing three timeswith bufferA plus 25mM imidazole, 0.5%Triton
X-100, and 0.5% Tween 20, followed by three times with buffer
A plus 25 mM imidazole. The beads were heated to 85 °C for 5
min in SDS sample buffer (100 l). scFv bound protein were
analyzed by immunoblot.
Subcellular Fractionation and Turnover—Fractionation was as
described in the manufacturer’s handbook (ThermoScientific
subcellular fractionation kit). Fractions were analyzed by SDS-
PAGE and immunoblotting. IRF-1 half-life was determined as
described previously (6).
RESULTS
Screening for scFv Binding to aC-terminal Peptide from IRF-1—
A biotinylated C-terminal IRF-1 peptide (LDSLLTPVRLP-
SIQAIPCAP, referred to as peptide 22 in Fig. 2) was immobi-
lized on streptavidin-coated immunotubes and used to screen
phage expressing single chain variable fragments (scFv) from
the Tomlinson library (I or J) to generate Mf1 domain-specific
reagents (Fig. 1a). Boundphagewas eluted and amplified before
being used for further rounds of selection as detailed under
“Materials andMethods” (Fig. 1b). The pool of scFv (polyclonal
pool) after the final round was infected into HB2151 bacteria,
and 48 individual colonies were picked for each library (96 col-
onies in total). These were screened for monoclonal scFvs that
bound to full-length IRF-1 following secretion from the phage-
infected bacteria into culturemediumupon inductionwith iso-
propyl 1-thio--D-galactopyranoside. First, the polyclonal pool
of scFv was assayed to make sure it contained nanobodies that
could bind peptide 22 when in the context of full-length IRF-1.
A nitrocellulose filter coated with GST-tagged IRF-1 (0.3
mg/ml) was incubated with the polyclonal scFv and developed
using HRP-linked to protein A. This gave a positive signal for
the polyclonal scFv nanobodies when compared with a control
(Fig. 1c). When soluble monoclonal scFvs, from the 96 individ-
ual bacterial colonies, were subsequently screened in this assay,
five of the clones reproducibly gave a strong positive signal (Fig.
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FIGURE 1. Screening for IRF-1 scFv nanobodies. a,Mf1 (multifunctional-1) domain of IRF-1 is located at the extreme C terminus and has been shown to play
a role in transcriptional regulation and degradation. b, schematic of antibody phage display protocol. c, left panel, diagram of scFv binding to full-length IRF-1
in a dot blot format. Right panel,polyclonal scFvs secretedbyphage-infectedbacteria into culturemediawere spotted onto a nitrocellulosemembrane coated
withGST-IRF-1. After extensivewashing, bound scFvsweredetectedusingproteinA-HRPandenhancedchemiluminescence. The controlwas scFv-free culture
media. d, as in c except following the culture of individualmonoclonal scFv colonies. e, SDS-polyacrylamide gel showing the fivemonoclonal scFv nanobodies
identified in d, following expression by phage-infected HB2151 E. coli and secretion into 2 TY growth medium.
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1d). These five monoclonal scFvs (Fig. 1e) were taken forward
for characterization to determine both their specificity and
ability to bind to IRF-1 under different conditions.
When the phagemid DNA corresponding to the five positive
clones was sequenced, surprisingly all five clones consisted of
only a light chain. The restriction sites SfiI/NcoI and XhoI,
between which the heavy chain should have been cloned, were
intact as was the intervening pIT2 vector sequence present in
the unrestricted vector. However, numerous studies on func-
tional single domain antibodies have shown that they can
exhibit specific binding activity (15,
16) and that the light chain can
prove to be a highly active paratope
(17, 18).
Characterization of Recombinant
scFv Nanobodies Binding to the C
Terminus of IRF-1—To generate
a reproducible supply of purified
scFv, phagemid DNA was sub-
cloned into a gateway donor vector.
From there, the scFvs were trans-
ferred into pDEST14 for expression
in Escherichia coli with the existing
His/Myc tags or pDEST15, where
an additional GST tag was added, as
we found that this aided the expres-
sion of soluble scFv protein in
E. coli. Following purification using
glutathione-Sepharose, the GST-
scFvs were used as primary antibod-
ies in a series of assays aimed at
establishing binding specificity for
the target antigen. First, a biotin-
tagged peptide library spanning
the length of IRF-1 (Fig. 2a) was
used in a binding assay (Fig. 2, b and
c). The individual peptides were
immobilized and incubated with
the nanobodies (Fig. 2, b and c).
Alternatively, the peptides were
incubated with a commercial anti-
peptide polyclonal sera to the C-ter-
minal 20 amino acids of IRF-1 or
with streptavidin-HRP to demon-
strate peptide normalization. Fig. 2c
shows that all the nanobodies
bound to peptide 22, which was
used in the original library screen,
and that scFv1 and -3–5 also bound
to the highly related peptide 21 (Fig.
2, a and c, inset).
The ability of the scFv nanobod-
ies to bind IRF-1 under denaturing
conditions was determined by im-
munoblot; this demonstrated that
all the nanobodies were able to
detect purified His-IRF-1 (Fig. 2d)
and exogenous untagged-IRF-1
from crude cell lysate (Fig. 2e), but it did not bind to a closely
related family member IRF-2 when either purified His-IRF-2
(Fig. 2d) or exogenous IRF-2 (Fig. 2e), present in cell lysates, was
probed.
Capturing IRF-1 from Cells Using Nanobodies—Having
established that the five scFv nanobodies chosenwere all able to
recognize the peptide antigen (Fig. 2c) and the epitope present
in denatured IRF-1 protein (Fig. 2, d and e), they were subse-
quently characterized for their ability to bind IRF-1 under non-
denaturing conditions. First, a titration of GST-IRF-1 immobi-
FIGURE2. scFvbinding todenatured IRF-1.a, list of overlappingpeptides covering the complete sequenceof
IRF-1 used in c. Peptide 22was used for phage screening. b, schematic of scFv binding to biotinylated peptides
in a peptide binding assay. c, immobilized overlapping peptides (peptides 1–22; given in a) were incubated
witheach scFv (1g/ml). Followingextensivewashing, scFvbindingwasdetectedwith ananti-Hismonoclonal
antibody and enhanced chemiluminescence. A commercial anti-IRF-1 C-terminal peptide antibody was used
as a control, and peptide normalizationwas demonstrated usingHRP-streptavidin to detect the biotinmoiety.
The sequences of two overlapping peptides (21 and 22) are shown in the inset. d,purified His-IRF-1 (lane 1) and
His-IRF-2 (lane 2) (0.3 g/lane) were analyzed on a 12% SDS-PAGE/immunoblot and probed with anti-His,
anti-IRF-1, anti-IRF-2 and the scFv nanobodies (1 g/ml). scFv binding was detected using anti-GST mono-
clonal antibody, and enhanced chemiluminescence. A colloidal stain shows the purity of His-IRF-1 and His-
IRF-2. e, lysates from HeLa cells transfected with 1 g of pcDNA3 IRF-1 (lane 1) or pcDNA3 IRF-2 (lane 2) were
analyzed by 12% SDS-PAGE/immunoblot and probed with the antibodies listed in dwith the exception of the
anti-His antibody. NS, nonspecific band detected by the anti-GST antibody. The data are representative of at
least two independent experiments.
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lized on a microtiter plate was probed with either the
nanobodies or anti-GST (Fig. 3a, upper panel). (For all experi-
ments involving GST-IRF-1, scFvs were expressed without the
GST tag using pDEST14 and were purified on nickel-agarose.)
This showed that all five of the scFvs were able to bind IRF-1,
although there were reproducible differences in their ability to
form stable complexes. Interestingly, when full-length IRF-1
was replaced by a truncation mutant (IRF-1C25) from which
the C-terminal 25 amino acids had been removed, as expected
scFv1–3 and -5 were no longer able to detect the protein; how-
ever, scFv4 binding was unaffected, suggesting that this nano-
body is not specific for its C-terminal epitope under the condi-
tions of the assay (Fig. 3a, lower panel). When the assay was
performed in the alternative orientation (Fig. 3b), a more pro-
nounced difference in stable binding was detected. In this case,
scFv3 bound significantly better than the remaining nanobod-
ies, with the exception of the nonspecific nanobody scFv4.
To expand on the functionality of the scFv nanobodies, their
binding to IRF-1 from cell lysates was investigated and com-
pared with a control scFv (scFvN) selected from the ETH gold
library for binding to a domain from an N-terminal region of
IRF-1 (amino acids 60–124; data not shown). When the nano-
bodies were immobilized on nickel agarose-beads and incu-
bated with HeLa cell lysate overexpressing full-length IRF-1,
scFv3 and scFvN (Fig. 3c, lanes 7 and 13), and to a lesser extent
scFv5 and scFv2, captured IRF-1 (lanes 11 and 5). scFvN could
also capture IRF-1C25 (Fig. 3c, lane 14), as it recognizes an
N-terminal epitope, whereas scFv2, -3, and -5 were shown to be
specific for the C terminus by their failure to pull down IRF-
1C25 (Fig. 3c, lanes 6, 8, and 12). Again the nonspecific nature
of scFv4 was demonstrated as it bound weakly to both full-
length andC25 IRF-1 protein (Fig. 3c, lanes 9 and 10).Wenext
determined if any of the nanobodies were able to deplete
endogenous IRF-1 from cell lysates (Fig. 3d). scFv3 bound
endogenous IRF-1 with sufficient affinity to deplete all the pro-
tein from the lysate (Fig. 3d, compare lanes 5 and 12). Consis-
tent with the previous results, scFv5 showed weak binding (Fig.
3d, lanes 7 and 14) as did scFv4. The nonspecific nature of scFv4
was highlighted further by its ability to bind to GAPDH,
whereas all the other scFv showed no GAPDH binding activity
(Fig. 3d, middle panel).
As scFv3 could bind endogenous IRF-1, it appeared to be the
best candidate for cell-based studies. However, before moving
on to generate scFv3-based mammalian expression vectors,
we first carried out an EMSA to establish whether scFv3 could
bind to IRF-1 when it was in complex with DNA. Fig. 3e (lanes
12–14 compared with lane 1) shows that scFv3 binds to DNA-
bound IRF-1 producing a “supershifted” IRF-1-DNA complex,
whereas scFvN, although efficient at capture of endogenous
IRF-1 from detergent-soluble lysates (Fig. 3d), showed no sig-
nificant binding to the IRF-1- NA complex suggesting its
epitope is masked in this situation (Fig. 3e, lanes 4–6). Consis-
tent with its low affinity for IRF-1, scFv2 displayed a weak band
shift activity.
Mapping the scFv Nanobody Epitopes—The data presented
above demonstrate that although all five of the scFv nanobodies
are able to bind to denatured IRF-1 with a similar affinity, they
show considerable variation in their ability to bind both recom-
binant and cellular IRF-1 under nondenaturing conditions,
suggesting that they have differing sequence specificities. To
investigate this, we used a peptide library in which the amino
acids of peptide 22 were sequentially mutated to Ala (Fig. 4a).
The nanobodies showed distinct requirements for bindingwith
no two scFvs having the same epitope specificity (Fig. 4c). Inter-
estingly the two nanobodies that were able to specifically cap-
ture cell-expressed full-length IRF-1, scFv3, and scFv5, both
require the Pro residues at positions 322 and 325. scFv3 also had
a strong requirement for three other residues (Ser317, Leu310,
and Thr311), whereas scFv5 required only one other residue
(Pro312), and this is likely to explain why scFv3 binds with a
higher apparent affinity than scFv5. The nonspecific nature of
scFv4 is explained by its very limited epitope as it displayed a
strong requirement for only two adjacent amino acids Pro316
and Ser317, a sequence that is also found in the main body of
IRF-1 and inGAPDH.As expected, scFvNdid not bind to any of
the C-terminal peptides but was specific for its N-terminal
epitope (Fig. 4b). Together, the characterization of the C-ter-
minal scFv nanobodies suggested that scFv3 has properties that
make it the best candidate for the development of an intracel-
lular nanobody.
scFv Nanobodies Activate Exogenous IRF-1 in Cells—To
determine whether the specific interaction of a nanobody with
the Mf1 domain of IRF-1 in a cellular environment had conse-
quences for IRF-1 transcriptional activity, scFv3, together with
control nanobodies (scFv2 and scFvN), was cloned into amam-
malian GFP expression vector. scFv2 was chosen to act as a
control for scFv3 as these two nanobodies are highly similar in
sequence (Fig. 5a), with only five variant amino acids through
the CDR2 and CDR3 regions, but they have differing affinities
and amino acid specificities. scFvNwas used as a second control
antibody, in preference to a nonspecific nanobody, as it again
has good sequence conservation with scFv3 (Fig. 5a) but binds
out with the IRF-1 C-terminal domain.
FIGURE 3. Binding of the scFv to IRF-1 under nondenaturing conditions. a, titration (0–200 ng) of immobilized GST-IRF-1WT or GST-IRF-1C25 was
incubated with the scFv nanobodies (1 g/ml). Binding was detected with anti-His/enhanced chemiluminescence and compared with anti-GST binding. The
results are given as relative light units (RLU) for scFv bindingplotted against IRF-1 amount and are representative of two separate experiments. b, as in a except
that the scFv was immobilized and GST-IRF-1 was in the mobile phase; binding was detected using anti-IRF-1. c, scFv nanobodies immobilized on Ni-NTA-
agarose beads were incubated with HeLa cell lysate (500 g) expressing either wild-type or IRF-1C25 protein, and bound proteins were analyzed by
SDS-PAGE/immunoblots developedusing an anti-IRF-1monoclonal antibody and enhanced chemiluminescence. d, scFv nanobodies immobilized onNi-NTA-
agarose beads were incubated with untransfected HeLa cell lysate (500 g). Following extensive washing, bound proteins were analyzed by SDS-PAGE/
immunoblotdevelopedwitheither anti-IRF-1or anti-GAPDH; alternatively, thegelwas stainedwith colloidal blue (bottompanel). The results are representative
of two independent experiments. e, EMSA where purified GST-IRF-1 (200 ng) binds a 32P-labeled DNA probe (consisting of 4 ISRE; lane 1) to give a banding
pattern consisting of two IRF-1-DNA complexes, labeled S1 and S2. DNA-bound IRF-1 can be supershifted by a commercial anti-IRF-1 antibody (lane 2). scFvN
2 and3were used at 200 ngper reactionwith a titration of IRF-1 (0, 50, 100, and 200ng; lanes 3–6, 7–10, and 11–14). The data are representative of at least three
independent experiments.
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scFv3 effects on transcriptional activity of IRF-1 were
assessed using a TLR3 reporter (19). Fig. 5b shows the effect on
reporter activity when a fixed amount of IRF-1 was expressed
together with a titration of either the C-terminal binding nano-
bodies, scFv3 and scFv2, or the N-terminal nanobody scFvN.
scFv3 significantly increased gene expression from the TLR3
promoter, under conditions where, although expressed at com-
parable levels, scFvN if anything slightly suppressed IRF-1
activity. Consistent with its weak C-terminal binding activity,
scFv2 showed very weak activity as an activator of IRF-1.
scFv3 was further tested for the ability to modulate IRF-1
activity on other known target promoters, specifically IFN
(20) and Cdk2 (5, 21). Fig. 5c shows that as well as activating
IRF-1 at the TLR3 promoter (lane 4 versus lane 3), scFv3 also
stimulated expression from the IFN promoter (lane 12 versus
lane 11). The scFv3 effect is specific for the IRF-1 response
element as mutant forms of the TLR3 (Fig. 5c, lanes 5–8) and
IFN (lanes 13–16) promoter, in which the ISRE is absent, were
not stimulated by the nanobody.
scFv3 appears to specifically target
the transcription activating func-
tion of IRF-1 as no enhancement of
its ability to repress expression from
the Cdk2 promoter was detected
(Fig. 5c, lanes 17–20).
To control for off-target effects of
scFv3 on IRF-1 activity, the above
experiment was repeated using IRF-
1C25 instead of wild-type protein
(Fig. 5d). As expected from our pre-
vious studies (5), IRF-1C25 had
a higher intrinsic transcriptional
activity against the IFN (Fig. 5d,
lanes 3) andTLR3 (lane 11) promot-
ers and was unable to repress Cdk2
promoter activity (lane 19) when
compared with the wild-type pro-
tein (Fig. 5c). However, no addi-
tional enhancement of IRF-1C25
activity was observed in the pres-
ence of scFv3 (Fig. 5d, compare
lanes 3 and 4, 11 and 12), suggesting
the scFv3 nanobody affects IRF-1-
mediated transcription through a
direct interaction with the C-termi-
nal regulatory domain rather than
through another domain of IRF-1 or
through binding to other proteins in
the initiator complex.
scFv3 Activates Endogenous IRF-1
Activity—As scFv3 could activate
exogenous IRF-1 in a cellular envi-
ronment, we extended the study to
look at the potential effect of scFv3
on endogenous IRF-1 using both
reporter constructs (Fig. 6, a and b)
and endogenous readouts (Fig. 6c).
When a titration of scFv3 and scFvN
was introduced into HeLa cells (Fig. 6a), it showed scFv3 could
increase luciferase production from both the TLR3 and IFN
promoters by 4–5-fold at the peak. In contrast, scFvN had no
significant effect on IRF-1 activity with either of the promoters
used. Furthermore, when the result was confirmed using addi-
tional physiologically relevant reporters (Fig. 6b) based on the
IRF-1-responsive promoter regions from TRAIL (13) and IL-7
(14) scFv3 could activate the WT reporters but not reporters
previously shown to be defective in IRF-1 binding (13, 14). As
expected from Fig. 6a, scFvN had no significant effect on either
TRAIL or IL-7 expression (Fig. 6b).
We next sought to use changes in the level of endogenous
proteins for IRF-1 target genes as a readout of its activity as a
transcriptional activator for PKR (22, 23) and ISG20 (24) gene
expression. Fig. 6c shows that scFv3 expression induced the
levels of the ISG20 and PKR proteins by 8- and 2.5-fold,
respectively (lane 3 versus lane 1, band intensity quantified
using SynGene Imaging Systems; data not shown). In agree-
FIGURE 4. Identification of scFv epitopes. a, immobilized biotinylated peptides, including an alanine scan of
the last 20 amino acids of IRF-1 LDSLLTPVRLPSIQAIPCAP, were incubated with 1 g/ml scFv1–5. scFv binding
was detected with anti-His. A peptide containing the epitope for scFvN is labeled as Co, and the data are
representative of two independent experiments. b, as in a except using scFvN. c, diagrammatic representation
of the amino acid motifs targeted by scFv1–5.
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ment with the data in Fig. 5c, scFv3 had little effect on the levels
of Cdk2. Moreover, neither scFv2 nor scFvN had any measura-
ble effect on ISG20, PKR, or Cdk2 levels. The data showing an
increase in the levels of both ISG20 andPKR suggest that scFv3-
activated IRF-1 is able to induce transcription from endoge-
nous promoters as well as reporter constructs.
One interpretation of the data presented here, showing that
the scFv3 nanobody can significantly increase IRF-1 transcrip-
tional activity, is that the C terminus of the endogenous protein
is rate-limiting for IRF-1-mediated gene activation and that the
nanobody functions by relievingMf1-imposed negative regula-
tion. Alternatively, as the Mf1 domain is involved in protein
interactions, which impact on IRF-1 localization (8) and degra-
dation (6), scFv3 may affect IRF-1-mediated transcription
through an indirect mechanism.
scFv3 Nanobody Decreases the Half-life of IRF-1—Possible
changes in the localization of IRF-1 were investigated using
subcellular fractionation. Fig. 7a shows that in untransfected
HeLa cells IRF-1 is almost exclusively detected in the soluble
nuclear compartment (fraction 3), and this is not affected by the
presence of either scFv3 or scFvN, providing evidence that
the nanobodies co-localize with IRF-1 (Fig. 7a, left panel) in the
nucleus but do not affect its localization. The C terminus of
IRF-1 is known to be required for its efficient turnover (6). The
half-life of soluble endogenous IRF-1 protein was therefore
measured in cycloheximide-treated cells that had been trans-
fected with scFv3 or scFvN, and this was compared with the
half-life in untransfected or EGFP alone expressing cells. Two
independent experiments are shown that are representative of a
total of five such experiments (Fig. 7, b and c; GAPDH control
given in supplemental figure). In each case, scFv3 caused a
decrease in the half-life of detergent-extractable IRF-1 to
around 17min (Fig. 7, b and c; scFv3), from a value of 41 min in
the EGFP alone expressing cells and 77 min in cells expressing
scFvN (Fig. 7, b and c; vector or EGFP and scFvN). Interestingly,
the rate of degradation of scFv3 itself was similar to that of
IRF-1 when the nanobody was present (Fig. 7b) suggesting that
scFv3-IRF-1 may be co-degraded. It is possible that binding of
scFv3 to IRF-1 changes detergent solubility rather than the half-
life per se; IRF-1 remaining in the pellet following re-extraction
under denaturing conditions was therefore measured. As with
the soluble fraction, the half-life of insoluble IRF-1 appeared to
be reduced in the presence of scFv3, compared with the con-
trols (Fig. 7d).
Together the above results suggest that the observed increase
in IRF-1 activity caused by binding of scFv3 to the Mf1 domain
(Figs. 5 and 6)was not due to a change in localization of IRF-1 or
to a decrease in the rate of its degradation. It also suggests that,
in addition to its previously documented role as a requirement
for efficient degradation of IRF-1, the Mf1 domain may also be
involved in preventing IRF-1 from being degraded too rapidly.
Introduction of a Single Point Mutation at the C Terminus of
IRF-1Mimics the Effect of scFv3 Nanobody Binding—We found
it of interest that the increase in IRF-1 transcriptional activity
seen in the presence of scFv3 was accompanied by a significant
decrease in the half-life of the protein, especially as deletion of
the Mf1 domain has previously been associated with an
increase in IRF-1 t0.5 (6).We therefore sought independent evi-
dence that the Mf1 domain, as well as being required for effi-
cient degradation of IRF-1 (6, 7), might also act as a “brake” on
IRF-1 turnover. During characterization of C-terminal trunca-
tion mutants, we have previously noted that a construct from
which the C-terminal four residues had been deleted was
expressed in cells atmuch lower levels thanwild-type IRF-1 (5).
We therefore investigated whether mutations in the extreme C
terminus of IRF-1 increased its rate of degradation andwhether
this was reflected in a gain of transcriptional activity. The min-
imal mutation that affected the level of IRF-1 expression was
found to be the substitution of Pro325 at the extremeC terminus
with Ala (IRF-1P325A). Fig. 8a shows that this mutant is
expressed at low levels, but it accumulates in the presence of the
proteasome inhibitor MG132. To investigate the difference in
expression of wild-type IRF-1 and the P325A mutant, their
half-lives were determined in cycloheximide-treated cells. The
t0.5 for both the detergent-soluble and -insoluble fraction of
P325A-IRF-1 was significantly less than that of the wild-type
protein (Fig. 8b). Thus, mutation of Pro325 is sufficient to signal
an increase in the rate of IRF-1 degradation.
Having identified a residue within the C-terminal 25 amino
acids of IRF-1, which when mutated had a similar effect on
IRF-1 degradation to scFv3 nanobody binding, we asked
whether this mutant had a higher intrinsic transcriptional
activity (Fig. 8c). When the activity of IRF-1P325A was deter-
mined on the TLR3 promoter, the mutant consistently dis-
played significantly higher activity (Fig. 8c) than the wild-type
protein. The difference in activity is accentuated when expres-
sion levels are taken into account (Fig. 8d). Thus, although at
each point 2-fold more IRF-1P325A vector was transfected
than wild-type vector, to compensate for the shorter half-life of
the mutant protein, quantitation demonstrates that the wild-
type protein was still expressed at higher levels (Fig. 8d, right
panel). Thus the P325A mutant is more active that the wild-
type protein as a transcriptional activator, providing indepen-
dent evidence that the C terminus of IRF-1 can limit the rate at
which the protein is degraded and that changes in the rate of
degradation correlate with increases in the activity of IRF-1 as
an activator of gene expression.
FIGURE 5. scFv3 nanobody activates exogenous IRF-1-dependent transcription. a, table showing sequence variation between CDRs (complementarity
determining regions) 2 and 3 of scFv2, -3, and -N. b, titration (0–250 ng) of EGFP-scFv2, -scFv3, and -scFvN were expressed in HeLa cells together with a
TLR3(ISRE)-luc reporter (120 ng), Renilla (60 ng), and IRF-1 (75 ng) as shown. DNA levels were normalized using an empty vector. Reporter gene activity was
measured in relative light units (RLU) and is expressed as the ratio of Luc/Ren. The assays were carried out in duplicate; results are given as mean half the
range and are representative of at least three independent sets of experiments. The immunoblot shows the levels of EGFP-scFv detected using anti-EGFP.
c,HeLa cellswere transfectedwith TLR3-Luc, TLR3(-ISRE)-Luc, IFN-p125luc, IFN(-ISRE)-p55luc, or Cdk2-luciferase reporter constructs (120ng),Renilla (60 ng),
and IRF-1 (100 ng) plus EGFP-scFv3 (100 ng) as indicated and reporter activity determined as in a. Expressed proteins were detected by immunoblot using
anti-EGFP and anti-IRF-1, and GAPDH was detected as a loading control. d, as in c except that IRF-1 was replaced with IRF-1C25. Reporter assays are
representative of at least two independent experiments.
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DISCUSSION
Data are presented suggesting that the Mf1 domain of IRF-1
limits its ability to activate transcription and that this negative
regulation can be relieved using
nanobodies that bind to the Mf1
domain or bymutating theC-termi-
nal residue of the protein (Pro325).
In addition, the data highlight a pos-
sible role for the Mf1 domain in
coordinating a link between the rate
of IRF-1 degradation and its tran-
scriptional activity. Previous studies
have suggested that IRF-1 activity is
regulated primarily at the level of
transcription as IRF-1 steady state
levels increase in response to agents
such as interferon and DNA dam-
age, which induce its transcriptional
activity (3, 25). However, we dem-
onstrate here that IRF-1 is also sub-
ject to post-translational regulation;
it is held in a latent or partially active
state, and activity can be induced in
the absence of an increase in its
steady state levels.
The Mf1 domain is a 25-amino
acid region in the extreme C termi-
nus of IRF-1, which appears to be a
“hot spot” for the regulation of both
its function and turnover. Thus, the
Mf1 domain has been shown to
house an LXXLL coregulator signa-
ture motif (amino acids 306–310),
which is essential for IRF-1-medi-
ated repression of Cdk2 (5) and a
binding site for members of the
Hsp70 family of molecular chaper-
ones that play a role in maintaining
the normal cellular function of
IRF-1 (8). The Mf1 domain lies
within a region originally defined as
an enhancer region (amino acids
257–325) required for maximal
IRF-1 transcriptional activity (26)
that most likely functions through
the recruitment of coactivators such
as p300 (27). More detailed analysis
of the IRF-1C terminus has revealed
that removal of the last 25 residues,
rather than the entire enhancer
domain, does not compromise its
ability to activate gene expression. Rather a C-terminal
25-residue IRF-1 truncation mutant displayed an increase in
FIGURE 6. scFv activates endogenous IRF-1. a, HeLa cells were transfected with a titration of EGFP-scFv3 or EGFP-scFvN (0–250 ng) plus Renilla (60 ng) and
either TLR3-Luc (120 ng) (left-hand graph) or IFN-p125luc (right-hand graph) (120 ng). DNA levels were normalized using an empty vector. Reporter gene
activitywasmeasured in relative light units (RLU) and is expressed as the ratio of Luc/Ren. The assayswere carried out in duplicate; results are given asmean
half the range andare representative of at least three independent sets of experiments. Expressedproteinsweredetectedby immunoblot using anti-EGFP and
anti-IRF-1, and GAPDH was detected as a loading control. b, HeLa cells were transfected with either TRAIL-Luc (WT or mutant-ISRE) or IL-7-Luc (WT or mutant
-ISRE) (120 ng), in each case with or without EGFP-scFv3 or EGFP-scFvN (120 ng). Reporter assays and immunoblots were carried out as above. c, lysate from
HeLa cells transfectedwith0, 0.5, or 1gof EGFP-scFv3 (lanes 1–3), EGFP-scFv2 (lanes 4–6), or EGFP-scFvN (lanes 7–9)were analyzedbySDS-PAGE/immunoblot
and probed with anti-ISG20, anti-PKR, anti-CDK2, anti-EGFP, anti-IRF-1, or anti-GAPDH antibody.
FIGURE7. scFv3decreases thehalf-life of IRF-1.a,HeLa cellswereuntransfected (control) or transfectedwith
EGFP-scFv3 or EGFP-scFvN (1.2 g) and fractionated after 24 h. Fraction 1, cytosol; fraction 2, membrane/
organelle; fraction 3, soluble nuclear proteins; fraction 4, detergent-insoluble nuclear fraction; fraction 5,
cytoskeletal proteins. Fraction 6was generated by resuspending the residual pellet in SDS sample buffer. The
fractions were analyzed by SDS-PAGE/immunoblot (IB) and probed with anti-IRF-1, anti-EGFP, anti-HP1 (a
nuclear localizationmarker), and anti-caspase 3 (a cytosolic localizationmarker). The data are representative of
two independent experiments. b, HeLa cells were untransfected or transfected with pDEST53 (EGFP alone),
EGFP-scFvN, or scFv3 (0.6 g). Post-transfection (24 h), the cells were treated with cycloheximide (30 g/ml)
and harvested at 0, 15, 30, 45, 60, 90, and 120 min. Detergent-soluble proteins were analyzed by SDS-PAGE
immunoblot developed using anti-EGFP or anti-IRF-1 monoclonal antibody. Two independent experiments
are shown, and they are representative of a total of five such experiments. c,natural logarithm (ln) of (%protein
remaining)was calculated for the data inb, andplotted against time (inminutes) to obtain a linear graphof the
form y  mx  c (m  slope, c  y-intercept). A mean graph was drawn, and the time at y  ln(50) was
calculated from the equation of the mean line. This value represents the calculated half-life (t0.5)  half the
range. d,detergent-insoluble pellet from bwas solubilized in sample buffer and analyzed by SDS-PAGE/immu-
noblot developed using an anti-IRF-1 monoclonal antibody.
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intrinsic transactivation potential when compared with the
full-length protein (Fig. 5) (5). This suggests that the extreme
C terminus, later named multifunctional-1 (Mf1) domain
(8), might be a negative regulator of IRF-1 activity. As these
studies relied on the use of transiently expressed IRF-1
mutant proteins, it has not been possible to determine the
effect of the Mf1 domain on IRF-1 as a transcriptional acti-
vator under normal cellular conditions. By developing a
nanobody that can bind to both endogenous and exogenous
IRF-1, we have been able to demonstrate that the Mf1
domain is normally rate-limiting for IRF-1-mediated gene
expression. The data presented in this study are in good
agreement with our previous observations using Ala scan-
ning and a series of truncation mutants to narrow down the
possible negative regulatory domain (5) to amino acids 311–
317. As the scFv3 interaction with IRF-1 requires both Tyr311
and Ser317 (Fig. 4), its activation of IRF-1-mediated gene
expression lends strong support to the idea that these resi-
dues include a negative regulatory motif (5).
Previous studies have shown that single chain nanobodies
can be used to modulate the function of their target antigens
in a cellular environment by, for example, altering the intra-
cellular localization of the target proteins (18, 28–30), neu-
tralizing enzyme activity (31), disrupting normal protein-
protein interactions (32–35), or affecting DNA-protein
interactions (32). In this study, the scFv3 nanobody was able
to activate IRF-1-mediated transcription between 4- and
8-fold making it a powerful tool to study the functions of the
Mf1 domain in a cell system. Conventional monoclonal anti-
bodies and nanobodies have been used previously to study a
negative regulatory domain in p53. Monoclonals and scFv,
which bind to the 421 epitope, have been used to explore the
role of the p53 C-terminal domain in negative regulation of
its DNA binding and transcriptional activity (36–38). In
addition, 421 antibody-based scFvs have been suggested as a
way to partially reactivate mutant forms of the p53 protein in
cells (39). The mechanism of p53 activation by 421 antibod-
ies is through an increase in the sequence-specific DNA
binding activity of the protein. In this study, we found no
evidence for an increased DNA binding activity of IRF-1 in
the presence of scFv3 (Fig. 3e) nor was there any obvious
difference in the subcellular localization of IRF-1 when
bound to the activating nanobody (Fig. 7a). Nanobody bind-
ing may impact on the conformation/dynamics of the IRF-1
structure or attenuate inhibition mediated via an intramo-
lecular interaction. The IRF-1-related protein IRF-3 is sub-
ject to this type of regulation. In the case of IRF-3, autoinhi-
bition occurs due to an interaction between the C terminus
and a region from the N-terminal domain (40), and this proc-
ess is regulated by C-terminal phosphorylation (41). How-
ever, structural information is only available for the DNA
binding domain of IRF-1 (42), and how the Mf1 domain
relates to the overall tertiary structure of the protein remains
to be determined. It is also possible that the Mf1 domain can
act as an allosteric modulatory site in response to C-terminal
binding proteins. To date, few IRF-1 interactions have been
documented, and the number of proteins known to interact
with the C terminus is even more limited. However, Hsp70
family members have recently been identified as physiolog-
ically relevant Mf1 interacting factors that impact on IRF-1
localization, transcriptional activity, and its rate of degrada-
tion (8) suggesting that the activity of IRF-1 is likely to be
modulated by agents that mimic or disrupt Mf1 protein-
protein interactions.
Increased IRF-1 degradation upon scFv3 binding (Fig. 7,
b–d) seems contrary to our previous observation that the
Mf1 domain is required for efficient IRF-1 turnover (6).
However, the Pro325 IRF-1 mutant protein displays a similar
property as it has a reduced t0.5 compared with the wild-type
protein (Fig. 8b). As nanobody epitope mapping (Fig. 4)
shows that scFv3 also has a strong requirement for Pro325, its
effect on degradation seems unlikely to be an artifact. The
Mf1 domain therefore appears to contain elements that are
both required for efficient degradation of IRF-1 (6) and that
prevent the rate of degradation from being too rapid (Figs. 7
and 8), i.e. the Mf1 can act like a rheostat “fine-tuning” IRF-1
turnover dependent on cellular conditions.
Both scFv3-bound IRF-1 and P325A IRF-1 have increased
transactivation activity, as well as an increased rate of degrada-
tion, making it interesting to speculate that these two Mf1
domain functions may be linked. It is increasingly clear that
both the proteolytic and nonproteolytic functions of the pro-
teasome are required for correct regulation of the transcrip-
tional machinery, with evidence of both the 19 S and 26 S pro-
teasomes being associated with chromatin, components of the
basal transcription machinery, and/or various transcription
factors (43–48). The precise mechanism(s) linking transcrip-
tional activation with protein degradation remain unclear.
However, evidence suggests roles for proteasome-mediated
degradation in establishing limits for transcription, promoting
the exchange of transcription factors on chromatin, and stim-
ulating multiple rounds of transcription initiation (49–54). It
will therefore be of interest to determine exactly howchanges in
the half-life of IRF-1 relate to its function as a transcription
factor.
FIGURE 8. Mutation of Pro325 mimics scFv3 binding to IRF-1. a, A375 cells were transfected with IRF-1WT and IRF-1P325A (0.5 g); 24 h later they were
treated with MG132 (50 M) and harvested at the times shown. IRF-1 was detected following analysis of the lysates by 10% SDS-PAGE/immunoblot. The data
are representative of two separate experiments. b, HeLa cells were transfected with IRF-1WT or IRF-1P325A and 24 h later treated with cycloheximide (30
g/ml) and then harvested at the times shown. Detergent-soluble lysate (right panel) and the residual pellet from the detergent extraction solubilized using
SDS-PAGE sample buffer (left panel) were analyzed by SDS-PAGE immunoblot developed using anti-IRF-1, and the data are representative of at least three
experiments. c and d,HeLa cells were transfectedwith TLR3-luc (120 ng), Renilla (60 ng), and a titration of either IRF-1WT (0–0.25g) or IRF-1P325A (0–0.5g)
DNA to allow for normalized protein expression (varying expression levels of WT and mutant IRF-1 previously determined, data not shown). Reporter gene
activity was measured in relative light units (RLU) and is expressed as the ratio of Luc:Ren (c). The assays were carried out in duplicate; results are given as
meanhalf the range and are representative of at least two independent sets of experiments.Wild-type and IRF-1P325Aprotein normalizationwas shownby
SDS-PAGE/immunoblot developed using anti-IRF-1 monoclonal antibody (d, left panel),and the data from the gel was quantified using a SynGene imaging
system and are given as relative light units against gel lane number (d, right panel).
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